CROMA POLYPHIL™ NEXT

Product Description

CROMA PhilArt NEXT is an injectable gel formulated with PN-HPT® (Polynucleotide High Purification Technology) and hyaluronic acid. This premium dermal filler product leverages advanced molecular science to stimulate natural collagen synthesis and enhance cellular regeneration. 

The CROMA PhilArt NEXT formulation delivers 20mg of polynucleotides and 20mg of hyaluronic acid per 2 ml pre-filled syringe, providing medical professionals with a precise solution for aesthetic procedures. 

CROMA PhilArt NEXT Dosage and Administration

Professional administration of CROMA PhilArt NEXT requires precise injection techniques and appropriate dosage protocols. The recommended dosage involves administering 1-2 ml of PhilArt per treatment session, distributed across the targeted areas using intradermal injection techniques.

Treatment protocols typically involve three to four sessions spaced 14–21 days apart for optimal results. Medical practitioners should utilize serial puncture or linear retrograde injection techniques with appropriate spacing between injection points. Maintenance treatments with CROMA are recommended every 4–6 months to sustain therapeutic benefits.

Ingredient Information

CROMA PhilArt NEXT contains precisely formulated active ingredients designed for optimal therapeutic efficacy. The primary components include 20mg of PN-HPT® polynucleotides and 20mg of hyaluronic acid per 2ml formulation.

The polynucleotide component utilizes advanced purification technology, derived from European freshwater fish sources meeting pharmaceutical-grade standards. These biocompatible molecules stimulate cellular regeneration and promote natural repair mechanisms within dermal tissues. The CROMA product formulation excludes lidocaine, making it suitable for patients with local anesthetic sensitivities.

Storage Instructions

Proper storage of CROMA PhilArt NEXT ensures product integrity and therapeutic efficacy throughout its shelf life. The products require storage at controlled temperatures between 2 °C and 25°C to maintain formulation stability and potency. 

Healthcare facilities must protect products from direct sunlight and extreme temperature fluctuations. Freezing temperatures can damage the polynucleotides and hyaluronic acid components, compromising therapeutic effectiveness.

CROMA PhilArt NEXT Contraindications

CROMA PhilArt NEXT has specific contraindications that practitioners must evaluate before initiating treatment:

• Allergies to polynucleotides, hyaluronic acid, or any product components

• Active skin infections at proposed injection sites

• Inflammatory conditions at the proposed injection sites

• Pregnancy

• Breastfeeding

• Autoimmune disorders (require careful evaluation)

CROMA PhilArt NEXT Precautions and Warnings

Healthcare professionals must observe specific precautions during administration to ensure patient safety and optimal therapeutic outcomes. Strict aseptic techniques are mandatory during treatment procedures to prevent infection. 

Patients on anticoagulant medications may experience an increased risk following injections. Medical practitioners should assess bleeding risk and consider appropriate precautions when medically appropriate.

CROMA PhilArt NEXT Manufacturer and Regulatory Information

CROMA Pharma manufactures PhilArt NEXT under stringent pharmaceutical quality standards, ensuring consistent product quality and therapeutic efficacy. The product is certified with CE marking, indicating compliance with relevant medical device regulations and safety standards. Each unit includes batch coding for complete traceability and quality control purposes. 

When healthcare professionals buy CROMA PhilArt NEXT or order CROMA PhilArt NEXT for their medical practices, they invest in proven regenerative technology backed by extensive clinical research and pharmaceutical-grade manufacturing standards.